References
- Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52. https://doi.org/10.1164/rccm.200510-1666ST
- Sherif IO, Al-Gayyar MM. Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite. Eur Cytokine Netw 2013;24:114-21.
- Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. "Silymarin", a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011;14:308-17.
- Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond) 2008;5:18. https://doi.org/10.1186/1743-7075-5-18
- Jahan S, Khan M, Imran S, Sair M. The hepatoprotective role of Silymarin in isoniazid induced liver damage of rabbits. J Pak Med Assoc 2015;65:620-2.
- Liu Q, Garner P, Wang Y, Huang B, Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008;8:365. https://doi.org/10.1186/1471-2458-8-365
- Joint Committee for the Revision of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2014.
- Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012;107:1380-7. https://doi.org/10.1038/ajg.2012.138
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7. https://doi.org/10.1164/rccm.200206-626OC
- Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med 2015;15:334. https://doi.org/10.1186/s12906-015-0861-7
- Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-52. https://doi.org/10.1111/j.1440-1746.2005.04048.x
- Saukkonen JJ, Powell K, Jereb JA. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med 2012;185:598-9. https://doi.org/10.1164/rccm.201112-2174ED
- Lee CM, Lee SS, Lee JM, Cho HC, Kim WS, Kim HJ, et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. Korean J Intern Med 2016;31:65-72.
- Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3:37-49. https://doi.org/10.1016/j.jceh.2012.12.001
- Wu S, Xia Y, Lv X, Tang S, Yang Z, Zhang Y, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients. J Gastroenterol Hepatol 2015;30:540-5. https://doi.org/10.1111/jgh.12717
Cited by
- Analytical Validation of Silymarin in Milk Thistle Extract as a Functional Health Ingredient using the UPLC System vol.22, pp.2, 2017, https://doi.org/10.13050/foodengprog.2018.22.2.145
- Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/3192351
- Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review vol.33, pp.6, 2019, https://doi.org/10.1002/ptr.6361
- Silymarin in Preventing Anti-Tuberculosis and Antipsychotic Drug-Induced Liver Injury at Different Doses and Treatment Times: A Systematic Review vol.21, pp.10, 2017, https://doi.org/10.5812/ircmj.94743
- Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis vol.13, pp.11, 2017, https://doi.org/10.1080/17512433.2020.1835468
- Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice vol.10, pp.3, 2021, https://doi.org/10.3390/antiox10030390
- Different drug metabolism behavior between species in drug-induced hepatotoxicity: limitations and novel resolutions vol.40, pp.4, 2017, https://doi.org/10.1080/15569543.2019.1639060
- Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs vol.16, pp.1, 2021, https://doi.org/10.1186/s13020-021-00543-x